Karen Akinsanya and Other Insiders Acquire Shares of NAUT
Several insiders, including Karen Akinsanya, bought NAUT shares in June, showing potential confidence in the company.
Key Points
- On June 18, 2026, Karen Akinsanya and other insiders bought 45,000 shares each of NAUT, suggesting insider confidence.
- Shares of NAUT traded at $2.31 on Tuesday, with recent insider purchases possibly indicating positive sentiment.
- Institutional activity includes new positions from Vanguard and Clearstead, while analysts have mixed ratings on NAUT.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Karen Akinsanya, alongside several other insiders, purchased 45,000 shares of NAUT on June 18, 2026. This insider buying activity may suggest confidence in the company's future prospects.
Insider Buying and Selling at Nautilus Biotechnology, Inc.
On June 18, 2026, Karen Akinsanya and other insiders, including Matthew McIlwain, Matthew Posard, Melissa Epperly, Farzad Nazem, and CEO Sujal Patel, were involved in purchasing shares of NAUT. Each insider, except Patel, bought 45,000 shares, although the transaction value wasn't specified. These purchases were not part of a pre-planned trading program, indicating a potential vote of confidence in the company's direction.
Other Institutional Activity in NAUT
In recent institutional activity, Vanguard Capital Management LLC and Clearstead Advisors, LLC both opened new positions in NAUT. Vanguard acquired 2,545,597 shares valued at approximately $9.88 million, while Clearstead added 2,329,784 shares worth about $9.04 million. Meanwhile, A16Z Capital Management, Perceptive Advisors, and Comprehensive Financial Management maintained their existing stakes without any change in shares.
Nautilus Biotechnology, Inc. Stock Up 160.8%
Shares of NAUT traded at $2.31 on Tuesday. The stock's recent trading activity may reflect the market's reaction to insider purchases and other institutional moves. As of the latest data, NAUT's market dynamics include various analyst ratings and institutional holdings, suggesting a diverse range of investor opinions.
$NAUT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On February 27, 2026, Guggenheim maintained a 'buy' rating on NAUT with a price target of $4.00. Previously, Goldman Sachs downgraded the stock to 'sell' with a target of $1.75 in December 2024. Meanwhile, Morgan Stanley maintained a 'hold' rating with a $5.00 target in July 2024, highlighting mixed analyst sentiment.
Bottom Line
The recent insider purchases by Karen Akinsanya and others at NAUT could indicate positive sentiment from those close to the company. While insider buying can be a bullish signal, it's important to consider it as part of a broader investment picture that includes institutional activity and analyst ratings. Investors should remember that these insider trades were reported post-factum and may not reflect current insider sentiment.
Get Nautilus Biotechnology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NAUT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.